Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system

Aoyama, Katsuyuki; Kuroda, Shigetoshi; Morihiro, Toshiaki; Kanaya, Nobuhiko; Kubota, Tetsushi; Kakiuchi, Yoshihiko; Kikuchi, Shinichi; Nishizaki, Masahiko; Kagawa, Shunsuke; Tazawa, Hiroshi; Fujiwara, Toshiyoshi

doi:10.1038/s41598-017-14717-x

Cited by 27 publications

(17 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A broad range of nucleic acid cargos had been delivered using liposomal formulations in GI cancers (Ozpolat et al, 2014;Harrison et al, 2018). Liposomal formulations of plasmid DNA had been explored in multiple studies with intraperitoneal colon cancers (Kline et al, 2009;Lan et al, 2010;Aoyama et al, 2017). To further increase the stability of the plasmid cargo and achieve improved control over drug release, several polymers like polyethylenimine, poly-L-lysine, and other cationic polymers and polycations had been used to complex with anionic DNA and encapsulate in liposomal nanoparticles (Goodwin and Huang, 2014).…”

Section: Payloads and Applications In Gi Cancer Therapymentioning

confidence: 99%

Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers

Das

Huang

2018

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers like liver, pancreatic, colorectal, and gastric cancer remain some of the most difficult and aggressive cancers. Nanoparticles like liposomes had been approved in the clinic for cancer therapy dating as far back as 1995. Over the years, liposomal formulations have come a long way, facing several roadblocks and failures, and advancing by optimizing formulations and incorporating novel design approaches to navigate therapeutic delivery challenges. The first liposomal formulation for a GI cancer drug was approved recently in 2015, setting the stage for further clinical developments of liposomebased delivery systems for therapies against GI malignancies. This article reviews the design considerations and strategies that can be used to deliver drugs to GI tumors, the wide range of therapeutic agents that have been explored in preclinical as well as clinical studies, and the current therapies that are being investigated in the clinic against GI malignancies. This work is supported by the National Institutes of Health [Grant CA198999]. L.H. is a cofounder of OncoTrap, Inc. No other potential conflicts of interest relevant to this article are reported.

show abstract

Section: Payloads and Applications In Gi Cancer Therapymentioning

confidence: 99%

Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers

Das

Huang

2018

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…Compared with pure ECHO-7 virus replicating in 5 days, the efficacy of anti-cancer activity was delayed approximately of two days. This observation can be possibly explained by the fact that the internalization procedure and redox triggered degradation delayed the virus replication, assembly and release [ 37 , 42 ]. Our study also proves again the successful encapsulation and controlled release of OVs by this nanohydrogel delivery system.…”

Section: Resultsmentioning

confidence: 99%

“…It has been evidenced that electrostatic and polar interactions of external ligands in the extracellular environment initiate an avalanche of signal transduction cascade via integrin stimulation in cancer cells, triggering cancer cell proliferation [ 35 ] Recently, lipid-based non-viral nanocarrier, liposome and extracellular vehicles (EVs), have attracting attentions to be employed as protective carriers for OVs. The lipid bilayer membrane can provide an aqueous containing cave assisting the encapsulated OVs escape from the immune clearance, but also improving the uptake by target cells [ 36 , 37 , 38 ]. It is also possible to have un-encapsulated OV remained in the suspension which is still a challenge to purify the OV loaded liposomes/EVs from un-encapsulated OVs [ 37 , 39 , 40 , 41 , 42 ].…”

Section: Introductionmentioning

confidence: 99%

“…The lipid bilayer membrane can provide an aqueous containing cave assisting the encapsulated OVs escape from the immune clearance, but also improving the uptake by target cells [ 36 , 37 , 38 ]. It is also possible to have un-encapsulated OV remained in the suspension which is still a challenge to purify the OV loaded liposomes/EVs from un-encapsulated OVs [ 37 , 39 , 40 , 41 , 42 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy

et al. 2021

View full text Add to dashboard Cite

Oncolytic viruses (OVs) are emerging as promising and potential anti-cancer therapeutic agents, not only able to kill cancer cells directly by selective intracellular viral replication, but also to promote an immune response against tumor. Unfortunately, the bioavailability under systemic administration of OVs is limited because of undesired inactivation caused by host immune system and neutralizing antibodies in the bloodstream. To address this issue, a novel hyaluronic acid based redox responsive nanohydrogel was developed in this study as delivery system for OVs, with the aim to protect the OVs following systemic administration. The nanohydrogel was formulated by water in oil (W/O) nanoemulsion method and cross-linked by disulfide bonds derived from the thiol groups of synthesized thiolated hyaluronic acid. One DNA OV Ad[I/PPT-E1A] and one RNA OV Rigvir® ECHO-7 were encapsulated into the developed nanohydrogel, respectively, in view of their potential of immunovirotherapy to treat cancers. The nanohydrogels showed particle size of approximately 300–400 nm and negative zeta potential of around −13 mV by dynamic light scattering (DLS). A uniform spherical shape of the nanohydrogel was observed under the scanning electron microscope (SEM) and transmission electron microscope (TEM), especially, the successfully loading of OV into nanohydrogel was revealed by TEM. The crosslinking between the hyaluronic acid chains was confirmed by the appearance of new peak assigned to disulfide bond in Raman spectrum. Furthermore, the redox responsive ability of the nanohydrogel was determined by incubating the nanohydrogel into phosphate buffered saline (PBS) pH 7.4 with 10 μM or 10 mM glutathione at 37 °C which stimulate the normal physiological environment (extracellular) or reductive environment (intracellular or tumoral). The relative turbidity of the sample was real time monitored by DLS which indicated that the nanohydrogel could rapidly degrade within 10 h in the reductive environment due to the cleavage of disulfide bonds, while maintaining the stability in the normal physiological environment after 5 days. Additionally, in vitro cytotoxicity assays demonstrated a good oncolytic activity of OVs-loaded nanohydrogel against the specific cancer cell lines. Overall, the results indicated that the developed nanohydrogel is a delivery system appropriate for viral drugs, due to its hydrophilic and porous nature, and also thanks to its capacity to maintain the stability and activity of encapsulated viruses. Thus, nanohydrogel can be considered as a promising candidate carrier for systemic administration of oncolytic immunovirotherapy.

show abstract

“…Lipo-pTS showed the strong tumor-specific antitumor effect independent of coxsackie and adenovirus receptor (CAR) and decreased adenovirus-neutralizing antibodies (AdNAbs) in immune-competent mice. [264]. In another study, cationic liposome-targeted the murine endostatin gene, antiangiogenic agent, (Lipo/mEndo) suppressed the colon cancer growth and prolonged survival times of intraperitoneally injected mice.…”

Section: Colorectal Cancer Therapymentioning

confidence: 99%

In vivo gene delivery mediated by non-viral vectors for cancer therapy

Mohammadinejad

Dehshahri

Madamsetty

et al. 2020

Journal of Controlled Release

191

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system

Cited by 27 publications

References 37 publications

Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers

Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers

Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy

In vivo gene delivery mediated by non-viral vectors for cancer therapy

Contact Info

Product

Resources

About